Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adenoviral vector encoding VEGF-C LX-1101

A genetically engineered, replication-deficient adenovirus carrying the gene encoding for the human vascular endothelial growth factor C (VEGFC; VEGF-C; Flt4 ligand), with potential pro-angiogenic activity. Upon perinodal administration of the AdAptVEGF-C adenoviral vector LX-1101, the adenovirus infects cells and promotes expression of VEGF-C. In turn, VEGF-C induces vascular and lymphatic endothelial cell proliferation locally, and may help re-grow the lymphatic system and improve symptoms associated with lymphedema (LE). VEGF-C, a lymphatic growth factor, plays a key role in (lymph)angiogenesis and the functioning of the lymphatic system.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:AdAptVEGF-C adenoviral vector LX-1101
VEGFC-expressing gene therapeutic LX-1101
Foreign brand name:Lymfactin
Code name:LX 1101
LX-1101
LX1101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search